Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis

Journal of the Chinese Medical Association

Volumn 73, Issue 11, 2010, Pages 573-580

  Chou, Chen Liang ^a,b   Lee, Si Huei ^a,b   Lu, Shin Yo ^a   Tsai, Ko Lun ^a   Ho, Chung Yu ^a   Lai, Hsuan Chu ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Botulinum toxin type A; Intra articular injection; Knee osteoarthritis

Indexed keywords

BOTULINUM TOXIN A;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INJECTION SITE PAIN; JOINT STIFFNESS; JOINT SWELLING; KNEE OSTEOARTHRITIS; KNEE PAIN; MALE; MUSCLE ATROPHY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; QUALITY OF LIFE; SCORING SYSTEM; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT;

EID: 78549245829     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(10)70126-X     Document Type: Article

References (60)

1. Pisoni C, Giardini A, Majani G, Maini M International Classification of Functioning, Disability and Health (ICF) core sets for osteoarthritis: a useful tool in the follow-up of patients after joint arthroplasty. Eur J Phys Rehabil Med 2008, 44:377-385.
2. Burns R, Graney MJ, Lummus AC, Nichols LO, MartindaleAdams J Differences of self-reported osteoarthritis disability and race. J Natl Med Assoc 2007, 99:1046-1051.
3. Power JD, Badley EM, French MR, Wall AJ, Hawker GA Fatigue in osteoarthritis: a qualitative study. BMC Musculoskelet Disord 2008, 9:63.
4. Hootman JM, Helmick CG Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006, 54:226-229.
5. Perruccio AV, Power JD, Badley EM Revisiting arthritis prevalence projections: it's more than just the aging of the population. J Rheumatol 2006, 33:1856-1862.
6. Blomqvist P, Feltelius N, Ekbom A, Klareskog L Rheumatoid arthritis in Sweden: drug prescriptions, costs and adverse drug reactions. J Rheumatol 2000, 27:1171-1177.
7. Mahowald M, Singh JA, Dyskstra D Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotoxicity Res 2006, 9:179-188.
8. Matsuno H, Nakamura H, Katayama K, Hayashi S, Kano S, Yudoh K, Kiso Y Effects of an oral administration of glucosamine-chondroitin-quercetin glucoside on the synovial fluid properties in patients with osteoarthritis and rheumatoid arthritis. Biosci Biotechnol Biochem 2009, 73:288-292.
9. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
10. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514-1522.
11. Fary RE, Carroll GJ, Briffa TG, Gupta R, Briffa NK The effectiveness of pulsed electrical stimulation (E-PES) in the management of osteoarthritis of the knee: a protocol for a randomised controlled trial. BMC Musculoskelet Disord 2008, 9:18.
12. Aaron RK, Boyan BD, Ciombor DM, Schwartz Z, Simon BJ Stimulation of growth factor synthesis by electric and electromagnetic fields. Clin Orthop Relat Res 2004, 419:30-37.
13. Brighton CT, Wang W, Clark CC Up-regulation of matrix in bovine articular cartilage explants by electric fields. Biochem Biophys Res Commun 2006, 342:556-561.
14. Chou CL, Li HW, Lee SH, Tsai KL, Ling HY Effect of intra-articular injection of hyaluronic acid in rheumatoid arthritis patients with knee osteoarthritis. J Chin Med Assoc 2008, 71:411-415.
15. Petrella RJ, DiSilvestro MD, Hildebrand C Effects of hyaluro-nate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med 2002, 162:292-298.
16. Moseley J, O'Malley K, Petersen NJ, Menke TJ, Brody BA, Kuykendall DH, Hollingsworth JC, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002, 347:81-88.
17. Viliani T, Huber U, Pasquetti P, Poli P, Marcucci M, Popolizio A Rehabilitation after primary total hip replacement: comparison between Italian and international protocols. Eura Medicophys 2004, 40:67-74.
18. Ethgen O, Bruyère O, Richy F, Dardennes C, Reginster JY Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature. J Bone Joint Surg Am 2004, 86:963-974.
19. Monnier G, Tatu L, Michel F New indications for botulinum toxin in rheumatology. Joint Bone Spine 2006, 73:667-671.
20. Thant ZS, Tan EK Emerging therapeutic applications of botulinum toxin. Med Sci Monit 2003, 9:RA40-RA48.
21. Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, Poewe W Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000, 20:44-49.
22. Borodic GE, Acquadro M, Johnson EA Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 2001, 10:1531-1544.
23. Arezzo J Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 2002, 18:S125-S132.
24. Petersson IF, Boegård T, Saxne T, Silman AJ, Svensson B Radiographic osteoarthritis of the knee classified by the Ahlbäck and Kellgren & Lawrence systems for the tibiofemoral joint in people aged 35-54 years with chronic knee pain. Ann Rheum Dis 1997, 56:493-496.
25. McConnell S, Kolopack P, Davis AM The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum 2001, 45:453-461.
26. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
27. Felber ES Botulinum toxin in primary care medicine. J Am Osteopath Assoc 2006, 106:609-614.
28. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Botox Post-Stroke Spasticity Study Group, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002, 347:395-400.
29. Smith SJ, Ellis E, White S, Moore AP A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000, 14:5-13.
30. Wang HC, Hsieh LF, Chi WC, Lou SM Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 2002, 81:272-278.
31. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000, 69:217-221.
32. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001, 8:559-565.
33. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996, 46:1306-1310.
34. Lim JY, Koh JH, Paik NJ Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008, 39:126-131.
35. Wong SM, Hui AC, Tong PY, Poon DW, Yu E, Wong LK Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2005, 143:793-797.
36. Placzek R, Deuretzbacher G, Buttgereit F, Meiss AL Treatment of chronic plantar fasciitis with botulinum toxin A: an open case series with a 1 year follow up. Ann Rheum Dis 2005, 64:1659-1661.
37. Padberg M, de Bruijn SF, Tavy DL Neck pain in chronic whiplash syndrome treated with botulinum toxin: a double-blind, placebo-controlled clinical trial. J Neurol 2007, 254:290-295.
38. Pedreira G, Cardoso E, Melo A Botulinum toxin type A for refractory post-stroke shoulder pain. Arq Neuropsiquiatr 2008, 66:213-215.
39. Peng PW, Tumber PS Ultrasound-guided interventional procedures for patients with chronic pelvic pain: a description of techniques and review of literature. Pain Physician 2008, 11:215-224.
40. Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, Auff E A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 2006, 102:509-516.
41. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, Blitzer A, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987, 2:237-254.
42. Dressler D, Saberi FA, Barbosa ER Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005, 63:180-185.
43. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
44. Mense S Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004, 251:I1-I7.
45. Cui M, Khanijou S, Rubino J, Aoki KR Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125-133.
46. Kim DY, Oh BM, Paik NJ Central effect of botulinum toxin A in human. Int J Neurosci 2006, 116:667-680.
47. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004, 172:1529-1532.
48. Schaible HG, Grubb BD Afferent and spinal mechanisms of joint pain. Pain 1993, 55:5-54.
49. Mapp P, Kidd BL The role of substance P in rheumatic disease. Semin Arthritis Rheum 1994, 23:3-9.
50. Cerinic MM, Konttinen Y, Generini S, Cutolo M Neuropeptides and steroid hormones in arthritis. Curr Opin Rheumatol 1998, 10:220-235.
51. Garrett NE, Cruwys SC, Kidd BL, Tomlinson DR Effect of capsaicin on substance P and nerve growth factor in adjuvant arthritic rats. Neurosci Lett 1997, 230:5-8.
52. Konttinen YT, Kemppinen P, Segerberg M, Hukkanen M, Rees R, Santavirta S, Sorsa T, et al. Peripheral and spinal neural mechanisms in arthritis, with particular reference to treatment of inflammation and pain. Arthritis Rheum 1994, 37:965-982.
53. Schaible HG, Schmelz M, Tegeder I Pathophysiology and treatment of pain in joint disease. Adv Drug Deliv Rev 2006, 58:323-342.
54. Cui M, Aoki KR Botulinum toxin type A (BTX-A) reduced inflammatory pain in the rat formalin model. Cephalgia 2000, 20:414.
55. Purkiss J, Welch M, Doward S, Foster K Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000, 59:1403-1406.
56. Cui M, Li Z, You S, Khanijous S, Aoki R Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Arch Pharmacol 2002, 365:R17.
57. Thumboo J, Chew LH, Soh CH Validation of the Western Ontario and McMaster University osteoarthritis index in Asians with osteoarthritis in Singapore. Osteoarthr Cartil 2001, 9:440-446.
58. Faucher M, Poiraudeau S, Lefevre-Colau MM, Rannou F, Fermanian J, Revel M Algo-functional assessment of knee osteoarthritis: comparison of the test-retest reliability and construct validity of the WOMAC and Lequesne indexes. Osteoarthr Cartil 2002, 10:602-610.
59. Bedson J, Croft PR The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord 2008, 9:116.
60. Williams FM, Spector TD Biomarkers in osteoarthritis. Arthritis Res Ther 2008, 10:101.